Back to Authors

Factor, Stewart Alan

0000-0002-0449-973X

A5054911069 | I150468666

Mayo Clinic

Emory University

Citations 10

Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004)

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.s27.004

APOE ɛ4-related differences in visuospatial impairment in female Parkinson’s Disease patients (743)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.743

Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001)

Neurology | December 6, 2023 | Volume: 84 | Issue: 14_supplement | Pages: No page available

10.1212/wnl.84.14_supplement.s15.001

Non‐motor phenotypic subgroups in adult‐onset idiopathic, isolated, focal cervical dystonia

Brain and Behavior | July 21, 2021 | Volume: 11 | Issue: 8 | Pages: No page available

10.1002/brb3.2292 | PMID 34291595

Abstract Background : Non‐motor symptoms are well established phenotypic components of adult‐onset idiopathic, isolated, focal cervical dystonia (AOIFCD). However, improved understanding of their clinical heterogeneity is needed to better target therapeutic intervention. Here, we examine non‐motor phenotypic features to identify possible AOIFCD subgroups. Methods : Participants diagnosed with AOIFCD were recruited via specialist neurology clinics (dystonia wales: n = 114, dystonia coalition: n = 183). Non‐motor assessment included psychiatric symptoms, pain, sleep disturbance, and quality of life, assessed using self‐completed questionnaires or face‐to‐face assessment. Both cohorts were analyzed independently using Cluster, and Bayesian multiple mixed model phenotype analyses to investigate the relationship between non‐motor symptoms and determine evidence of phenotypic subgroups. Results : Independent cluster analysis of the two cohorts suggests two predominant phenotypic subgroups, one consisting of approximately a third of participants in both cohorts, experiencing increased levels of depression, anxiety, sleep impairment, and pain catastrophizing, as well as, decreased quality of life. The Bayesian approach reinforced this with the primary axis, which explained the majority of the variance, in each cohort being associated with psychiatric symptomology, and also sleep impairment and pain catastrophizing in the Dystonia Wales cohort. Conclusions : Non‐motor symptoms accompanying AOIFCD parse into two predominant phenotypic sub‐groups, with differences in psychiatric symptoms, pain catastrophizing, sleep quality, and quality of life. Improved understanding of these symptom groups will enable better targeted pathophysiological investigation and future therapeutic intervention.
Clinimetric testing of the comprehensive cervical dystonia rating scale

Movement Disorders | March 14, 2016 | Volume: 31 | Issue: 4 | Pages: 563-569

10.1002/mds.26534 | PMID 26971359

ABSTRACT Introduction The aim of this study was to test the clinimetric properties of the Comprehensive Cervical Dystonia Rating Scale. This is a modular scale with modifications of the Toronto Western Spasmodic Torticollis Rating Scale (composed of three subscales assessing motor severity, disability, and pain) now referred to as the revised Toronto Western Spasmodic Torticollis Scale‐2; a newly developed psychiatric screening instrument; and the Cervical Dystonia Impact Profile‐58 as a quality of life measure. Methods Ten dystonia experts rated subjects with cervical dystonia using the comprehensive scale. Clinimetric techniques assessed each module of the scale for reliability, item correlation, and factor structure. Results There were 208 cervical dystonia patients (73% women; age, 59 ± 10 years; duration, 15 ± 12 years). Internal consistency of the motor severity subscale was acceptable (Cronbach's alpha = 0.57). Item to total correlations showed that elimination of items with low correlations (<0.20) increased alpha to 0.71. Internal consistency estimates for the subscales for disability and pain were 0.88 and 0.95, respectively. The psychiatric screening scale had a Cronbach's alpha of 0.84 and satisfactory item to total correlations. When the subscales of the Toronto Western Spasmodic Torticollis Scale‐2 were combined with the psychiatric screening scale, Cronbach's alpha was 0.88, and construct validity assessment demonstrated four rational factors: motor; disability; pain; and psychiatric disorders. The Cervical Dystonia Impact Profile‐58 had an alpha of 0.98 and its construction was validated through a confirmatory factor analysis. Conclusions The modules of the Comprehensive Cervical Dystonia Rating Scale are internally consistent with a logical factor structure. © 2016 International Parkinson and Movement Disorder Society
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS)

JAMA Neurology | November 16, 2015 | Volume: 73 | Issue: 1 | Pages: 102

10.1001/jamaneurol.2015.2736 | PMID 26569098

Cognitive profile of LRRK2‐related Parkinson's disease

Movement Disorders | February 4, 2015 | Volume: 30 | Issue: 5 | Pages: 728-733

10.1002/mds.26161 | PMID 25650144

AbstractBackgroundIncreasing evidence suggests that genetic factors play a role in the variability associated with cognitive performance in Parkinson's disease (PD). Mutations in the LRRK2 gene are the most common cause of monogenic PD; however, the cognitive profile of LRRK2‐related PD is not well‐characterized.MethodsA cohort of 1,447 PD patients enrolled in the PD Cognitive Genetics Consortium was screened for LRRK2 mutations and completed detailed cognitive testing. Associations between mutation carrier status and cognitive test scores were assessed using linear regression models.ResultsLRRK2 mutation carriers (n = 29) demonstrated better performance on the Mini Mental State Examination (P = 0.03) and the Letter‐Number Sequencing Test (P = 0.005). A smaller proportion of LRRK2 carriers were demented (P = 0.03).ConclusionsOur cross‐sectional study demonstrates better performance on certain cognitive tests, as well as lower rates of dementia in LRRK2‐related PD. Future longitudinal studies are needed to determine whether LRRK2 mutation carriers exhibit slower cognitive decline. © 2015 International Parkinson and Movement Disorder Society
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A–resistant cervical dystonia

Neurology | May 13, 2012 | Volume: 53 | Issue: 7 | Pages: 1431-1431

10.1212/wnl.53.7.1431 | PMID 10534247

Activity enhances dopaminergic long-duration response in Parkinson disease

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 | PMID 22459675

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion

Neurology | February 9, 2012 | Volume: 78 | Issue: 10 | Pages: 690-695

10.1212/wnl.0b013e318249f683 | PMID 22323755